Targeting key signalling pathways in oesophageal adenocarcinoma: A reality for personalised medicine?

Figure 2 Drug inhibition of signalling pathways. Drugs that target signalling pathways can be divided into two groups. Antibodies [Becazutumab, trastuzumab, cetuximab and matuzumab are antibodies that target the receptor tyrosine kinase (RTK), vascular epidermal growth factor receptor (VEGFR), human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor 1 (EGFR) respectively] and small molecular inhibitors (The small molecular inhibitors gefitinib and erlotinib target EGFR. Temsirolimus specifically inhibits the PI3-kinase pathway at the level of Raptor/mTOR. CI1040 and PD0325901 inhibits ERK MAP kinase pathway at the level of MEK. Sorafenib is a dual inhibitor of the VEGF receptor and ERK MAP kinase at the level of RAF).